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SUMMARY. The objective of the Zagreb 2016 classifi cation as the third modifi cation of the unique classifi cation of cervi-
cal cytology fi ndings based on the previous Zagreb 2002 and the latest Bethesda 2014 classifi cations is standardization 
of cervical cytology fi ndings for the whole Croatia, according to the latest concepts on the biologic behavior of cervical 
cancer and its precursors. Besides cytomorphological lesions, Zagreb 2016 includes recommendations for diagnostic-
therapeutic procedures in line with the international recommendations and the experience of Croatian cytologists and 
gynecologists. It was presented and accepted by Croatian clinical cytologists at the Croatian Society of Clinical Cytol-
ogy Convention held on December 12, 2016 in Zagreb. The main modifi cations relative to the Zagreb 2002 classifi cation 
refer to the following: classifi cation of ‘koilocytosis’, i.e. cytomorphological lesions associated with human papilloma-
virus, into the category of low-grade squamous intraepithelial lesions (LSIL); classifi cation of ‘atypical glandular cells 
– probably reactive lesions’ into the category of non-neoplastic lesions; and the introduction of ‘atypical glandular cells 
– not othervise specifi ed’ (AGC-NOS) into the category of abnormal glandular cells. In addition, the fi nding of endome-
trial cells in women aged ≥45 and absence of the transformation zone elements is highlighted.
Introduction
The Bethesda System (TBS) classifi cation of cervical 
cytology fi ndings was introduced nearly three decades 
ago, in 1988, fi rst in the USA, and then in most countries 
worldwide (1). TBS was developed in response to the 
requirement for a uniform and reproducible terminology 
to derive clear recommendations for clinical procedures. 
Based on the then novel concepts on cervical neoplasia, 
modifi cations of this classifi cation were adopted in 1991 
and 2001, aiming at reducing variations in cytologist in-
terpretation and improving the choice of further diagnos-
tic-therapeutic procedures (2,3). Upon recognizing the 
concepts that resulted in TBS terminology and based on 
our own experiences, a unique classifi cation of cervical 
cytology fi ndings known as Zagreb 1990 (4) and Zagreb 
2002 (5) was also introduced in Croatia, as modifi cations 
of the ori ginal TBS classifi cation and its amendments 
and/or changes.
Currently, instead of the conventional Pap test for de-
tection of cervical lesions, liquid-based cytology (LBC), 
as well as simultaneous testing (co-testing) for high-risk 
human papillomavirus (HR HPV) and Pap test have 
been increasingly applied, giving preference to the HR 
HPV test for primary screening. The approval and ever 
wider use of prophylactic HPV vaccine have entailed 
changes in the strategy of both screening for cervical 
cancer and its prevention and treatment (6,7). TBS prin-
ciples and terminology have also greatly infl uenced 
standardization of cytologic fi ndings in other localiza-
tions such as thyroid gland (8) and pancreas (9), urine 
cytology (10), as well as of histologic terminology for 
squamous lesions of the lower anogenital tract associ-
ated with HPV infection (11). In addition, guidelines for 
the treatment and follow up of cervical lesions have re-
cently been based on the principles involving the same 
procedures for the same risk (12). Guidelines for the 
procedures for abnormal cytology with triage, using HR 
HPV test, HPV testing in primary screening with the 
use of cervicovaginal cytology as a ‘refl ex’ triage test 
for positive HPV screening, and introduction of HPV 
vaccine have led to TBS updating in 2014 in order to 
upgrade morphological criteria and add new informa-
tion on cervical cytology (13). In the future policies of 
cervical cancer screening that include primary HPV 
screening, cytology has assumed the role of diagnostic 
test of high accuracy required for correct choice of fur-
ther workup or patient follow up.
Modifi cation of the Zagreb 2002 unique classifi ca-
tion of cervical cytology fi ndings (5) and the latest TBS 
2014 classifi cation (13) has resulted in a new modifi ca-
tion for Croatia named Zagreb 2016, presented and ad-
opted by the Croatian clinical cytologists at Convention 
of the Croatian Society of Clinical Cytology, Croatian 
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Figure 1. Unique classifi cation of cervical cytological fi ndings „Zagreb 2016“
Last name and first name: Date of birth:




  Satisfactory for interpretation/evaluation
  Unsatisfactory for interpretation/evaluation
   Specimen rejected /not processed
   Specimen examined, but evaluation of epithelial abnormality is  
not possible
Comments for the specimen adeuacy: 
  Incorrect label          
  Broken slide    
  Poor fixation or preservation
  Scant celluarity 
  No endocervical cylindrical cells
  No transformation zone cells
  Obscuring with leukocytes/inflammation  
  Blood obscuring
  Smeared in few levels     
  Forein material presence  
  Other:  
   
General categorization 
  Negative for intraepithelial lesion or maligancy  
  Abnormal cells  
Descriptive diagnosis
Microorganisms – cytomorphologically consistent with
  Bacillus vaginalis  Gardnerella vaginalis  
  Mixed flora  Actinomyces   
  Fungi  Cellular changes associated with HSV 
  Trichomonas  Other:   
   
Other non-neoplastic findings:
  Reactive cellular changes associated with:  
   Inflammation  IUD    
   Radiation  Other:                         
  Repair  Reserve cells
  Parakeratosis  Dyskeratoses  Hyperkeratosis 
  Endocervical cylindrical epithelium - reactive and stimulated 
  Squamous metaplastic epithelium – reactive and stimulated
  Glandular cells post hysterectomy
  Endometrial cells   
   of menstrual period   in postmenopause 
   ≥ 45 years of age  
  Atrophy 




 Atypical squamous cells (ASC)
   Of undetermined significance (ASC-US)
  Cannot exlude HSIL (ASC-H)
  Cannot exlude invasion
  Squamous intraepithelial lesion (SIL)
 Low grade SIL 
(LSIL)
 Changes associated with HPV / Koilocytosis
 CIN 1 / Mild dysplasia
 High grade SIL 
(HSIL)
 CIN 2 / Moderate dysplasia
 CIN 3
 severe dysplasia
 carcinoma  in situ
 Cannot exclude early invasion 
 Plus: cellular changes associated with HPV
 Squamous cell carcinoma 
Glandular cells Origin
 Atypical glandular cells (AGC)  Endocervical
 Endometrial
 Extrauterine
 Not otherwise 
specified 
  Not otherwise specified (AGC-NOS)





 Favor invasive 
lesion
 Adenocarcinoma in situ (AIS)
 Adenocarcinoma
 Atypical cells of undetermined significance
 Other malignant neoplasms
PAP TEST - ZAGREB 2016 UNIQUE FORM OF CYTOLOGIC FINDING OF UTERINE CERVIX








 Repeat smear   
 Repeat after therapy   
 Repeat in 6 months  








Pap test indication  Screening  Workup/diagnostic  Follow-up
Pap test specimen type  Conventional  Liquid-based cytology
Partus Cyclus LMP  Postmenopause
Contraception:  Hormones   IUD   Other   Without
Previous diagnostic-therapeutic procedures (cytology / histology / therapy / other)
HPV test (result / method / institution/date) Colposcopy (result /date)  
Signature of supervising physician






Clinical diagnosis:      w.n.l.   Other
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Referral Form Data Entered 
by the Gynecologist/Medical Doctor
Entering woman’s respective data is one of the pre-
conditions for appropriate cytologic analysis of the 
vaginal-cervical-endocervical (VCE) smear and Pap 
test. The referral form is fi lled out by the gynecologist/
medical doctor and should include the following: wom-
an’s last and fi rst name, smear ID number, date of birth, 
and personal identifi cation number (OIB) and/or identi-
fi cation number of the insured person (MBOO) by 
which the cytologic fi nding is computer linked to other 
woman’s fi ndings irrespective of the possible last name 
change. Besides clinical diagnosis, clinical data of in-
terest are parity, date of last menstruation, and contra-
ception or hormone therapy. In addition, previous diag-
nostic-therapeutic procedures (cytology, histology, 
therapy, etc.), their timing and results, and the last col-
poscopy fi nding are relevant for the cytologist. The sec-
tion in the Zagreb 2016 referral form that is fi lled out by 
the gynecologist also contains data on previous HPV 
test including the fi nding, method, institution, and date 
of HPV testing. New sections where indication for Pap 
test (screening, workup/diagnosis, or follow up) is en-
tered and type of Pap test (conventional or LBC) can be 
fi lled out by gynecologist or cytologist.
Sample Adequacy
Assessment of sample adequacy remains one of the 
most important components of Bethesda system to en-
sure quality (14). As in previous modifi cations, speci-
mens are classifi ed into two groups according to sample 
adequacy, ‘satisfactory’ and ‘unsatisfactory’ (3,5,13).
Satisfactory cytology sample means that the smears 
are thin-layered, cells are not overlapping, and all trans-
formation zone elements including squamous epithelium 
cells, metaplastic and endocervical cells are present. 
Cells are well preserved and the specimen contains at 
least 8,000–12,000 squamous cells in conventional smear 
and at least 5,000 cells in LBC sample. A simple method 
of fast determination of sample cellularity by use of “ref-
erence images” is proposed for conventional specimens 
and of representative fi elds of cell count for LBC speci-
mens. Notes on specimen inadequacy, specimen ob-
scured with leukocytes, blood or necrosis, lack of endo-
cervical columnar cells and transformation zone ele-
ments, presence of foreign material, poor cell fi xation or 
preservation can be listed in cytologic fi nding. Based on 
this information, the physicians taking samples can de-
cide on the need of repeating the test. In case of atrophy 
following chemo-irradiation therapy, hys terectomy or 
trachelectomy, minimal cellularity of 5000 and 2000 
cells, respectively, is considered satisfactory (6,15).
Unsatisfactory cytology sample mostly results from 
too low celularity, poor cell fi xation or preservation, 
sample obscured with blood, leukocytes or bacteria 
(>75% of squamous epithelium cells obscured), or 
strong cytolysis (>75% of squamous epithelium cells 
undergoing cytolysis). Assessment of specimen adequa-
cy is subjective and the cytologist should describe the 
reason for this fi nding evaluation (13).
General Categorization
Although ‘general categorization’ is an optional part 
of the classifi cation, it serves clinician for fast triage of 
cytologic fi ndings. Similar to previous classifi cation 
modifi cations (4,5), while aiming at rapid orientation in 
terms of negative/positive fi nding, only the following 
two groups have been retained: ‘negative for intraepi-
thelial or invasive lesion’ and ‘abnormal cells’, although 
Bethesda 2014 optionally suggests the group ‘others’ as 
well, referring to the fi nding of endometrial cells in 
women aged ≥45 (6,13).
Descriptive Diagnosis
Descriptive diagnosis includes ‘microorganisms’ and 
‘other non-neoplastic fi ndings’ that may be found along 
with the two above mentioned groups in ‘general cate-
gorization’, and ‘abnormal cells’, i.e. squamous, glan-
dular, atypical cells of undetermined signifi cance and 
other malignant neoplasms. A cytologic fi nding of ‘mi-
croorganisms’ refers to the microorganisms that are 
identifi ed directly or according to their cytopathic effect 
on the cells; Bacillus vaginalis prevails in normal vagi-
nal fl ora in women of generative age; mixed vaginal 
fl ora is a frequent fi nding but need not be associated 
with infl ammation; fungi are found in the form of spores 
and/or pseudomycelium, and mostly refer to Candida 
albicans; Trichomonas, a protozoan, usually causes se-
vere infl ammation; Actinomyces is usually found in in-
trauterine device (IUD) or pessary carriers, with or 
without cellular infl ammation; Gardnerella vaginalis is 
generally associated with the bacterial vaginosis syn-
drome, i.e. ‘shift in vaginal fl ora suggestive of bacterial 
vaginosis’ (13), causing unpleasant discharge and in-
fl ammation; lesions associated with the cytopathic ef-
fect caused by herpes simplex virus (HSV); ‘others’ re-
fer to cocci, diplococci and amebae. The CMV cyto-
pathic effect may also be detected in cervicovaginal 
smears and is highlighted in Bethesda 2014 (13).
Other non-neoplastic fi ndings include infl ammatory 
and reactive (irritating) lesions on the cells of squa-
mous, endocervical columnar and metaplastic epitheli-
um, alterations associated with radiotherapy and IUD, 
reparatory epithelium as a sign of cervicovaginal epi-
thelium lesion and infl ammation; reserve cells usually 
in atrophic smear or as a sign of damage and infl amma-
tion in generative age. Benign proliferative keratiniza-
tion alterations on squamous epithelial cells (parakera-
tosis, dyskeratosis, hyperkeratosis) and columnar cells 
found after hysterectomy are also listed among non-
neoplastic lesions. A fi nding of endometrial cells be-
yond menstrual cycle and in postmenopause, i.e. in 
women aged ≥45 (6,13) is considered pathologic and 
requires additional workup due to possible lesions in 
the endometrium or uterine body.
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Abnormal Cells
Squamous cells
Cytomorphological lesions of the stratifi ed squamous 
epithelium are categorized as in the previous modifi ca-
tion (5).
Atypical squamous cells (ASC) include various le-
sions which, according to defi nition, indicate that cyto-
logic changes of squamous epithelial cells are not dis-
tinct enough in quality or quantity to point to squamous 
intraepithelial lesion (SIL), and in rare cases to carci-
noma (16,17). This category is most common in the in-
terpretation of abnormal cervical cytology fi ndings 
since a number of non-neoplastic conditions can also 
induce cytologic changes that are interpreted as ASC, 
e.g., infl ammation, poor fi xation, atrophy with degen-
eration, hormonal effect, and other cellular artifacts.
In Zagreb 2016, ASC continues to be subcategorized, 
just as in Zagreb 2002 modifi cation (5), as follows: 
atypical squamous cells of undetermined signifi cance 
(ASC-US); atypical squamous cells – high-grade squa-
mous intraepithelial lesion (HSIL) cannot be excluded 
(ASC-H); and atypical squamous cells – invasion can-
not be excluded (ASC – invasion cannot be excluded). 
By defi nition, ASC-US denote cellular cytologic chang-
es that suggest low-grade squamous intraepithelial le-
sion at the most (LSIL) but the criteria for this interpre-
tation are not met completely (16,17). It is considered 
that no more than 2%–5% of cervicovaginal samples 
should be classifi ed in this category in a low-risk popu-
lation, whereas its prevalence in high-risk population 
may be two- to threefold greater (16,18,19). In this cat-
egory, SIL was detected in 29,1%–43% and invasive 
carcinoma in 1,7% of biopsy specimens (18,19). Cyto-
logic fi ndings of atypical parakeratosis, atypical repair, 
atypia in post menopause or atrophy, decidual cells, tro-
phoblast cells, and bare cell nuclei without cytoplasm 
have been frequently interpreted as ASC-US (13).
Atypical squamous epithelial cells suggesting high-
grade squamous intraepithelial lesion (ASC-H) are a 
subgroup of atypical/borderline lesions suspect of 
HSIL, and according to Bethesda classifi cation also of 
carcinoma in some cases (3,6). This category is used 
when the number of abnormal cells is so low that the 
diagnosis is uncertain and implies a fi nding of no more 
than 5%–10% of abnormal squamous cells. Cytologic 
interpretation of the ASC-H fi nding is related to atypi-
cal immature metaplasia, dense cell clusters, pro-
nounced atypical repair, severe atrophy, and post-irradi-
ation lesions associated with residual or recurrent carci-
noma (13). In order to differentiate cytologic pictures of 
ASC-H and potential invasion, the ASC – invasion can-
not be excluded category related to the previous ‘sus-
pect’ fi nding (20) and ‘abnormal’ fi nding in previous 
classifi cations (4) employed in Croatia, have now been 
retained in the Zagreb 2016 classifi cation. In the SIL 
group, the only modifi cation relative to the Zagreb 2002 
classifi cation (5) refers to cytologic interpretation of 
low-grade SIL; besides the above mentioned cellular 
changes suggesting cervical intraepithelial neoplasia 
grade 1 (CIN 1), i.e. mild dysplasia, it also includes le-
sions associated with HPV infection, mostly in the form 
of cytopathic effect, koilocytosis, as stated in Bethesda 
classifi cations (1,3,6,13).
Subdivision of the HSIL category remains the same 
as in the previous classifi cation (5). It should be noted 
that besides inclusion of particular SIL categories, a cat-
egory of cervical intraepithelial lesion (CIN), i.e. dys-
plasia/carcinoma in situ, has been included as in previ-
ous modifi cations employed in Croatia (4,5), providing 
the clinician with an option to choose the length of pa-
tient follow up or additional workup.
The category of ‘planocellular carcinoma/squamous 
carcinoma’ remains the same as in previous classifi ca-
tions (4,5).
Glandular (columnar) cells
Cytomorphological lesions of the columnar epithelial 
cells are relatively rare as compared with squamous 
epithelium. Similar to the previous modifi cation (5), 
these are divided into three groups: atypical glandular 
cells (AGC), adenocarcinoma in situ (AIS), and adeno-
carcinoma. Considering the great variety of cellular le-
sions, the origin of the columnar epithelium (endocervi-
cal,  endometrial, extrauterine, or undetermined) should 
be specifi ed in each group and subgroup of abnormal 
columnar cells.
Although AGC is a rare fi nding in cervicovaginal cy-
tology (0,19%–0,27%) (21–23), histopathologic exami-
nation reveals a wide spectrum of abnormalities in both 
squamous and columnar epithelium (24,25). This cate-
gory differs from the previous modifi cation (5) by intro-
ducing, besides the existing subgroups of AGC – in-
traepithelial lesion probable and AGC – invasive lesion 
probable, a new subgroup of atypical glandular cells not 
otherwise specifi ed (AGC-NOS) identical to the one 
found in the TBS classifi cation (3,6,13). Namely, ac-
cording to the recommendation of Croatian gynecolo-
gists (26) and re-evaluation based on cytologic analysis 
from three Croatian centers (Osijek, Rijeka and Zagreb) 
presented at the Sixty Years of Gynecologic Cytology in 
Petrova Hospital Symposium held on March 7, 2014, 
the AGC – reactive lesion probable has been reclassi-
fi ed into the group of ‘non-neoplastic lesions’, thus hav-
ing reduced the rate of fi ndings categorized as AGC and 
consequently the number of unnecessary workup proce-
dures.
The category of ‘adenocarcinoma in situ’ (AIS) has 
been recognized as a unique entity, as in the previous 
classifi cations (3,5), with a characteristic cytologic pic-
ture, just as the group of ‘adenocarcinoma’. It should be 
noted that endometrial or extrauterine adenocarcinoma 
can be differentiated from endocervical adenocarcino-
ma according to cytologic lesions, which should be 
clearly described in the fi nding form. Therefore, it is 
emphasized that the origin of columnar epithelium 
should be specifi ed in case of any AGC group or sub-
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group whenever possible, thus directing further diag-
nostic and therapeutic procedures (26,27).
Atypical cells of undetermined signifi cance
Cytomorphological lesions that do not correspond to 
any of the mentioned categories, while the cells do not 
show distinct characteristics of malignancy, should be 
interpreted as ‘atypical cells of undetermined signifi -
cance’. Atypical cells with pronounced degenerative 
changes or cells of mesenchymal origin, where differ-
ential cytologic diagnosis cannot be made, are most fre-
quently described in this category (5,6,13).
Other malignant neoplasms
The category of ‘other malignant neoplasms’ is a rare 
cytologic fi nding. Malignant cells do not originate from 
cervical squamous and/or columnar epithelium but sug-
gest other malignant lesions that may occur in the cer-
vix, either as variants of cervical carcinoma or as rare 
primary tumors occurring in the uterine body or adnexa 
(mesenchymal origin, lymphoma or melanoma origin). 
They can be recognized in cytologic specimens but dif-
ferential diagnosis is usually hampered by the very na-
ture of cytologic specimen and morphological overlap 
with other entities (5,6,13).
Instructions
At the end of the referral form, the cytologist pro-
vides instructions to the clinician, sometimes to im-
prove the quality of samples, and guidelines for diag-
nostic workup (26,27). These instructions should be 
precise and clear, based on relevant literature, repre-
senting cytologist’s recommendations based on the cy-
tologic fi nding and patient clinical data, as well as pre-
vious fi ndings and therapeutic procedures. The instruc-
tions should be phrased as suggestions, in line with the 
national and international clinical practice and guide-
lines (26,27).
Pap test, i.e. diagnostic cytology of the cervix, can be 
performed beyond the recommended screening inter-
vals within the workup in symptomatic patients, e.g., 
increased and abnormal discharge, abnormal bleeding 
in clinical picture or history, cervix of suspect appear-
ance, genital tumor growth, presence of condyloma, etc. 
(26). Repeat Pap test is required in case of unsatisfac-
tory samples. Post-therapeutic re-testing is required in 
case of detecting cells with very severe infl ammatory 
lesions and abundant leukocytes. In other non-neoplas-
tic fi ndings, earlier re-testing should not be ordered 
(6,13). If Pap test reveals pronounced disorders of kera-
tinization (parakeratosis, dyskeratosis and/or hyperker-
atosis), re-testing within 12 months can be suggested; if 
the cytologist considers cytologic follow up or HPV 
testing necessary within 6 months, such a fi nding should 
be re-classifi ed as ASC-US. Although representing neg-
ative Pap test fi nding, very pronounced reactive lesions 
of metaplastic squamous and endocervical columnar 
epithelium may occasionally also be the reason for the 
cytologist to recommend earlier re-testing. In the 
screening population, recommending earlier repeat Pap 
testing for non-neoplastic fi ndings should be used only 
 exceptionally. In case of endometrial cells beyond men-
struation, in postmenopause, and in women aged ≥45 
(if the date of last menstruation is not stated), examina-
tion of the endometrium (ultrasound, direct cytology or 
histopathology of the endometrium) should be recom-
mended. In case of atrophic epithelium with severe de-
generative changes, cytologic examination after local 
estrogen application can be ordered due to diffi culties in 
cell interpretation.
In case of abnormal cytologic fi nding, repeat exami-
nation in at least 6 months, HPV test, colposcopy and 
histology can be recommended, depending on the grade 
of epithelial abnormality and in line with guidelines for 
the diagnosis and treatment of cervical lesions (26,27).
Conclusion
The Zagreb 2016 classifi cation is a unique classi-
fi cation of cervical cytology fi ndings for Croatia. In 
comparison with the previous classifi cation (5), some 
modifi cations have been done in line with the interna-
tional recommendations (6,13) and based on the experi-
ences acquired by the Croatian cytologists and gyne-
cologists (26).
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